Fennec Pharmaceuticals Inc. (TSE:FRX – Get Free Report)’s share price hit a new 52-week high on Monday. The company traded as high as C$18.35 and last traded at C$18.35, with a volume of 591 shares traded. The stock had previously closed at C$16.56.
Fennec Pharmaceuticals Trading Up 2.7%
The firm has a market cap of C$676.80 million, a price-to-earnings ratio of -159.75 and a beta of 3.90. The company’s 50-day moving average is C$15.02 and its 200-day moving average is C$13.10.
Insider Buying and Selling
In other news, insider Pierre Sayad sold 12,000 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of C$17.18, for a total value of C$206,160.00. Following the sale, the insider directly owned 9,519 shares in the company, valued at approximately C$163,536.42. This trade represents a 55.76% decrease in their position. Also, insider Robert Christopher Andrade sold 106,844 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of C$16.63, for a total transaction of C$1,776,815.72. Following the completion of the sale, the insider owned 217,675 shares in the company, valued at C$3,619,935.25. This represents a 32.92% decrease in their position. Company insiders own 16.20% of the company’s stock.
Institutional Investors Weigh In On Fennec Pharmaceuticals
An institutional investor recently bought a new position in Fennec Pharmaceuticals stock. Cornerstone Capital Inc. acquired a new position in shares of Fennec Pharmaceuticals Inc. (TSE:FRX – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 105,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,129,000. Cornerstone Capital Inc. owned about 0.30% of Fennec Pharmaceuticals as of its most recent SEC filing. 16.86% of the stock is owned by hedge funds and other institutional investors.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.
Recommended Stories
- Five stocks we like better than Fennec Pharmaceuticals
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
